What is Fortress Biotech Inc's earnings per share (EPS)?

Fortress Biotech Inc (FBIO) reported diluted earnings per share of $-0.07 for fiscal year 2025. This represents a 97.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fortress Biotech Inc Financials

FBIO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Fortress Biotech Inc (FBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 36/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Fortress Biotech Inc has an operating margin of -111.0%, meaning the company retains $-111 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -191.4% the prior year.

Growth

Fortress Biotech Inc's revenue grew 9.7% year-over-year to $63.3M, a solid pace of expansion. This earns a growth score of 49/100.

Leverage

Fortress Biotech Inc carries a low D/E ratio of 1.05, meaning only $1.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Fortress Biotech Inc's current ratio of 2.49 indicates adequate short-term liquidity, earning a score of 47/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Fortress Biotech Inc generated -$65.8M in operating cash flow, capex of $20.0M consumed most of it, leaving -$85.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Fortress Biotech Inc's ROE of 13.7% shows moderate profitability relative to equity, earning a score of 41/100. This is up from -202.3% the prior year.

Piotroski F-Score Neutral

5/9

Fortress Biotech Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

-9.65x

For every $1 of reported earnings, Fortress Biotech Inc generates $-9.65 in operating cash flow (-$65.8M OCF vs $6.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-702.2x

Fortress Biotech Inc earns $-702.2 in operating income for every $1 of interest expense (-$70.2M vs $100K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$63.3M

YoY+9.7%

5Y CAGR+6.8%

10Y CAGR+53.6%

Fortress Biotech Inc generated $63.3M in revenue in fiscal year 2025. This represents an increase of 9.7% from the prior year.

EBITDA

-$65.6M

YoY+38.1%

Fortress Biotech Inc's EBITDA was -$65.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.1% from the prior year.

Net Income

$6.8M

YoY+114.8%

Fortress Biotech Inc reported $6.8M in net income in fiscal year 2025. This represents an increase of 114.8% from the prior year.

EPS (Diluted)

$-0.07

YoY+97.4%

Fortress Biotech Inc earned $-0.07 per diluted share (EPS) in fiscal year 2025. This represents an increase of 97.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$85.8M

YoY-7.0%

Fortress Biotech Inc generated -$85.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 7.0% from the prior year.

Cash & Debt

$79.4M

YoY+38.6%

5Y CAGR-19.4%

10Y CAGR-2.1%

Fortress Biotech Inc held $79.4M in cash against $52.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

32M

YoY+15.4%

Fortress Biotech Inc had 32M shares outstanding in fiscal year 2025. This represents an increase of 15.4% from the prior year.

Margins & Returns

Gross Margin

66.9%

YoY+3.1pp

5Y CAGR-1.1pp

10Y CAGR-33.1pp

Fortress Biotech Inc's gross margin was 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.

Operating Margin

-111.0%

YoY+80.4pp

5Y CAGR+95.7pp

10Y CAGR+5744.3pp

Fortress Biotech Inc's operating margin was -111.0% in fiscal year 2025, reflecting core business profitability. This is up 80.4 percentage points from the prior year.

Net Margin

10.8%

YoY+90.5pp

5Y CAGR+112.8pp

10Y CAGR+5622.4pp

Fortress Biotech Inc's net profit margin was 10.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 90.5 percentage points from the prior year.

Return on Equity

13.7%

YoY+216.0pp

5Y CAGR+60.0pp

10Y CAGR+98.8pp

Fortress Biotech Inc's ROE was 13.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 216.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$11.9M

YoY-79.0%

5Y CAGR-28.6%

10Y CAGR-8.8%

Fortress Biotech Inc invested $11.9M in research and development in fiscal year 2025. This represents a decrease of 79.0% from the prior year.

Share Buybacks

$700K

5Y CAGR+58.5%

Fortress Biotech Inc spent $700K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$20.0M

5Y CAGR+59.7%

10Y CAGR+53.1%

Fortress Biotech Inc invested $20.0M in capex in fiscal year 2025, funding long-term assets and infrastructure.

FBIO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$63.3M+9.7%	$57.7M-31.8%	$84.5M+11.6%	$75.7M+10.1%	$68.8M+50.9%	$45.6M
Cost of Revenue	$20.9M+0.2%	$20.9M-8.8%	$22.9M-25.6%	$30.8M-4.1%	$32.1M+119.8%	$14.6M
Gross Profit	$42.3M+15.1%	$36.8M-40.3%	$61.6M+37.0%	$45.0M+22.5%	$36.7M+18.4%	$31.0M
R&D Expenses	$11.9M-79.0%	$56.6M-46.6%	$106.1M-21.4%	$134.9M+4.7%	$128.9M+101.0%	$64.1M
SG&A Expenses	$96.4M+9.9%	$87.7M-3.6%	$91.0M-20.0%	$113.7M+30.9%	$86.8M+42.0%	$61.2M
Operating Income	-$70.2M+36.4%	-$110.4M+22.5%	-$142.3M+30.1%	-$203.6M-8.0%	-$188.5M-100.0%	-$94.3M
Interest Expense	$100K-99.3%	$13.5M-11.7%	$15.3M+22.7%	$12.5M-18.5%	$15.3M-0.1%	$15.3M
Income Tax	-$620K-298.7%	$312K-40.1%	$521K+16.0%	$449K-5.1%	$473K-5.4%	$500K
Net Income	$6.8M+114.8%	-$46.0M+24.1%	-$60.6M+30.0%	-$86.6M-33.8%	-$64.7M-39.1%	-$46.5M
EPS (Diluted)	$-0.07+97.4%	$-2.69+68.2%	$-8.47+47.0%	$-15.97	$-0.79	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$17.6M+7.4%	$16.4M+24.9%	$13.1M-13.1%	$15.1M+3.4%	$14.6M-1.8%	$14.9M+14.3%	$13.0M-34.7%	$19.9M
Cost of Revenue	$5.8M+16.5%	$4.9M+3.1%	$4.8M+2.4%	$4.7M+4.7%	$4.5M-21.9%	$5.7M-4.6%	$6.0M+167.0%	$2.2M
Gross Profit	$11.9M+3.5%	$11.5M+37.4%	$8.3M-20.0%	$10.4M+2.8%	$10.2M+10.8%	$9.2M+30.5%	$7.0M-60.3%	$17.7M
R&D Expenses	$208K-97.4%	$8.1M+106.3%	$3.9M-59.3%	$9.7M+2.4%	$9.4M-25.5%	$12.7M-49.0%	$24.8M+76.5%	$14.1M
SG&A Expenses	$17.4M-55.1%	$38.8M+51.0%	$25.7M-4.9%	$27.0M+22.6%	$22.0M+5.6%	$20.8M+16.1%	$17.9M-7.8%	$19.5M
Operating Income	-$6.8M+81.3%	-$36.5M-63.4%	-$22.3M+6.7%	-$23.9M-8.3%	-$22.1M+20.5%	-$27.8M+24.0%	-$36.6M-86.4%	-$19.6M
Interest Expense	$2.7M+8.9%	$2.5M-10.2%	$2.8M+8.1%	$2.6M-58.2%	$6.2M+192.6%	$2.1M-18.4%	$2.6M+26.3%	$2.1M
Income Tax	$26K	$0	$0-100.0%	$243K+252.2%	$69K	$0	$0-100.0%	$380K
Net Income	$5.8M-62.2%	$15.5M+246.3%	-$10.6M-56.5%	-$6.8M+47.4%	-$12.9M-17.5%	-$10.9M+29.0%	-$15.4M-66.1%	-$9.3M
EPS (Diluted)	$0.11-75.6%	$0.45+193.8%	$-0.48	N/A	$-0.76-4.1%	$-0.73+29.8%	$-1.04	N/A

FBIO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$185.5M+28.7%	$144.2M-13.9%	$167.5M-43.1%	$294.3M-25.8%	$396.5M+18.9%	$333.4M
Current Assets	$123.8M+37.0%	$90.4M-22.8%	$117.0M-49.2%	$230.4M-33.5%	$346.5M+30.2%	$266.1M
Cash & Equivalents	$79.4M+38.6%	$57.3M-29.2%	$80.9M-54.6%	$178.3M-41.7%	$305.7M+31.0%	$233.4M
Inventory	$9.6M-33.3%	$14.4M+41.4%	$10.2M-27.9%	$14.2M+43.6%	$9.9M+602.4%	$1.4M
Accounts Receivable	$29.8M+191.1%	$10.2M-32.8%	$15.2M-46.0%	$28.2M+22.0%	$23.1M-3.4%	$23.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$123.4M-15.4%	$145.9M-12.1%	$165.9M-32.1%	$244.3M-15.1%	$287.8M+23.5%	$233.1M
Current Liabilities	$49.7M-30.3%	$71.4M-15.9%	$84.9M-33.5%	$127.7M+26.4%	$101.0M+95.2%	$51.8M
Long-Term Debt	$52.4M-9.6%	$58.0M-4.8%	$60.9M-33.7%	$91.7M+113.6%	$42.9M-16.9%	$51.7M
Total Equity	$49.9M+119.3%	$22.7M+0.9%	$22.5M-46.0%	$41.7M-61.6%	$108.7M+8.3%	$100.3M
Retained Earnings	-$734.1M+0.9%	-$740.9M-6.6%	-$694.9M-9.6%	-$634.2M-15.8%	-$547.5M-13.4%	-$482.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$181.4M+13.5%	$159.9M-10.2%	$178.1M+23.5%	$144.2M+13.5%	$127.1M-12.8%	$145.7M-11.5%	$164.6M-1.7%	$167.5M
Current Assets	$118.5M+7.3%	$110.4M-13.0%	$126.9M+40.4%	$90.4M+4.7%	$86.3M-16.6%	$103.4M-11.3%	$116.5M-0.4%	$117.0M
Cash & Equivalents	$86.2M+15.9%	$74.4M-18.6%	$91.3M+59.5%	$57.3M-2.7%	$58.9M-22.8%	$76.2M-9.0%	$83.8M+3.5%	$80.9M
Inventory	$11.8M-8.0%	$12.9M+2.8%	$12.5M-13.4%	$14.4M+22.4%	$11.8M+21.7%	$9.7M-8.4%	$10.6M+3.7%	$10.2M
Accounts Receivable	$18.0M+15.0%	$15.6M-13.2%	$18.0M+76.2%	$10.2M-4.1%	$10.7M+2.0%	$10.5M+6.8%	$9.8M-35.6%	$15.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$116.2M-5.1%	$122.5M-15.8%	$145.6M-0.2%	$145.9M+37.7%	$105.9M-33.9%	$160.3M-4.9%	$168.6M+1.6%	$165.9M
Current Liabilities	$54.1M-6.0%	$57.5M-21.9%	$73.7M+3.2%	$71.4M+1.6%	$70.3M-6.9%	$75.5M-13.9%	$87.7M+3.3%	$84.9M
Long-Term Debt	$47.8M-4.5%	$50.0M-11.3%	$56.4M-2.7%	$58.0M+10.5%	$52.5M-21.7%	$67.0M+9.1%	$61.4M+0.9%	$60.9M
Total Equity	$55.9M+27.2%	$43.9M+97.4%	$22.3M-2.1%	$22.7M+7.5%	$21.2M+18.4%	$17.9M-22.4%	$23.0M+2.1%	$22.5M
Retained Earnings	-$730.1M+0.8%	-$736.0M+2.1%	-$751.5M-1.4%	-$740.9M-0.9%	-$734.1M-1.8%	-$721.2M-1.5%	-$710.3M-2.2%	-$694.9M

FBIO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$65.8M+18.0%	-$80.2M+37.5%	-$128.2M+28.5%	-$179.4M-53.9%	-$116.5M-39.3%	-$83.7M
Capital Expenditures	$20.0M	$0-100.0%	$63K-97.7%	$2.7M-40.5%	$4.6M+137.1%	$1.9M
Free Cash Flow	-$85.8M-7.0%	-$80.2M+37.5%	-$128.3M+29.6%	-$182.1M-50.4%	-$121.1M-41.5%	-$85.6M
Investing Cash Flow	$10.1M+167.5%	-$15.0M-613.3%	-$2.1M+90.8%	-$22.9M-156.6%	$40.5M+665.5%	-$7.2M
Financing Cash Flow	$77.4M+9.6%	$70.6M+115.8%	$32.7M-56.5%	$75.3M-49.4%	$149.0M-13.6%	$172.4M
Dividends Paid	$664K-4.3%	$694K-5.7%	$736K-1.7%	$749K0.0%	$749K+216.0%	$237K
Share Buybacks	$700K	N/A	N/A	N/A	N/A	$70K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.1M+77.8%	-$27.6M-40.9%	-$19.6M-51.6%	-$12.9M+35.7%	-$20.1M+8.1%	-$21.8M+14.0%	-$25.4M+27.3%	-$34.9M
Capital Expenditures	N/A	N/A	N/A	$0+100.0%	-$1.4M	N/A	N/A	$28K
Free Cash Flow	N/A	N/A	N/A	-$12.9M+39.8%	-$21.5M	N/A	N/A	-$35.0M
Investing Cash Flow	$2.9M-52.8%	$6.1M+422.4%	$1.2M+107.8%	-$15.0M	$0	$0	$0+100.0%	-$63K
Financing Cash Flow	$15.1M+233.4%	$4.5M-91.3%	$52.1M+102.1%	$25.8M+851.9%	$2.7M-81.0%	$14.3M-48.8%	$27.9M-36.1%	$43.6M
Dividends Paid	$166K0.0%	$166K0.0%	$166K0.0%	$166K-5.7%	$176K0.0%	$176K0.0%	$176K-2.2%	$180K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FBIO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	66.9%+3.1pp	63.8%-9.1pp	72.9%+13.5pp	59.4%+6.0pp	53.4%-14.6pp	68.0%
Operating Margin	-111.0%+80.4pp	-191.4%-23.0pp	-168.4%+100.3pp	-268.8%+5.3pp	-274.1%-67.3pp	-206.7%
Net Margin	10.8%+90.5pp	-79.8%-8.0pp	-71.8%+42.5pp	-114.3%-20.2pp	-94.1%+8.0pp	-102.0%
Return on Equity	13.7%+216.0pp	-202.3%+66.7pp	-269.0%-61.5pp	-207.5%-148.0pp	-59.5%-13.2pp	-46.4%
Return on Assets	3.7%+35.6pp	-31.9%+4.3pp	-36.2%-6.8pp	-29.4%-13.1pp	-16.3%-2.4pp	-14.0%
Current Ratio	2.49+1.2	1.27-0.1	1.38-0.4	1.80-1.6	3.43-1.7	5.14
Debt-to-Equity	1.05-1.5	2.55-0.2	2.70+0.5	2.20+1.8	0.40-0.1	0.52
FCF Margin	-135.6%+3.4pp	-139.0%+12.8pp	-151.8%+88.6pp	-240.4%-64.4pp	-176.0%+11.7pp	-187.7%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	67.4%-2.6pp	69.9%+6.4pp	63.5%-5.5pp	69.0%-0.4pp	69.4%+7.9pp	61.6%+7.6pp	53.9%-34.8pp	88.7%
Operating Margin	-38.6%+183.6pp	-222.2%-52.4pp	-169.8%-11.6pp	-158.3%-7.2pp	-151.0%+35.5pp	-186.5%+94.1pp	-280.6%-182.3pp	-98.3%
Net Margin	33.2%-61.2pp	94.3%+174.9pp	-80.5%-35.8pp	-44.7%+43.2pp	-88.0%-14.5pp	-73.5%+44.8pp	-118.3%-71.8pp	-46.5%
Return on Equity	10.5%-24.8pp	35.3%+82.8pp	-47.6%-17.8pp	-29.8%+31.1pp	-60.8%+0.4pp	-61.2%+5.7pp	-67.0%-25.8pp	-41.2%
Return on Assets	3.2%-6.5pp	9.7%+15.6pp	-5.9%-1.3pp	-4.7%+5.4pp	-10.1%-2.6pp	-7.5%+1.9pp	-9.4%-3.8pp	-5.5%
Current Ratio	2.19+0.3	1.92+0.2	1.72+0.5	1.27+0.0	1.23-0.1	1.37+0.0	1.33-0.0	1.38
Debt-to-Equity	0.86-0.3	1.14-1.4	2.53-0.0	2.55+0.1	2.48-1.3	3.75+1.1	2.67-0.0	2.70
FCF Margin	N/A	N/A	N/A	-85.4%+61.3pp	-146.6%	N/A	N/A	-175.3%

Similar Companies

Kala Pharmaceuticals Inc KALA

$155.1M

Corbus Pharmaceu CRBP

$180.4M

Adagene Inc. ADAG

$188.1M

Macrogenics Inc MGNX

$195.1M

Io Biotech, Inc. IOBT

$2.3M

Frequently Asked Questions

What is Fortress Biotech Inc's annual revenue?

Fortress Biotech Inc (FBIO) reported $63.3M in total revenue for fiscal year 2025. This represents a 9.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fortress Biotech Inc's revenue growing?

Fortress Biotech Inc (FBIO) revenue grew by 9.7% year-over-year, from $57.7M to $63.3M in fiscal year 2025.

Is Fortress Biotech Inc profitable?

Yes, Fortress Biotech Inc (FBIO) reported a net income of $6.8M in fiscal year 2025, with a net profit margin of 10.8%.

What is Fortress Biotech Inc's EBITDA?

Fortress Biotech Inc (FBIO) had EBITDA of -$65.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Fortress Biotech Inc have?

As of fiscal year 2025, Fortress Biotech Inc (FBIO) had $79.4M in cash and equivalents against $52.4M in long-term debt.

What is Fortress Biotech Inc's gross margin?

Fortress Biotech Inc (FBIO) had a gross margin of 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fortress Biotech Inc's operating margin?

Fortress Biotech Inc (FBIO) had an operating margin of -111.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Fortress Biotech Inc's net profit margin?

Fortress Biotech Inc (FBIO) had a net profit margin of 10.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Fortress Biotech Inc's return on equity (ROE)?

Fortress Biotech Inc (FBIO) has a return on equity of 13.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Fortress Biotech Inc's free cash flow?

Fortress Biotech Inc (FBIO) generated -$85.8M in free cash flow during fiscal year 2025. This represents a -7.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Fortress Biotech Inc's operating cash flow?

Fortress Biotech Inc (FBIO) generated -$65.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Fortress Biotech Inc's total assets?

Fortress Biotech Inc (FBIO) had $185.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Fortress Biotech Inc's capital expenditures?

Fortress Biotech Inc (FBIO) invested $20.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Fortress Biotech Inc spend on research and development?

Fortress Biotech Inc (FBIO) invested $11.9M in research and development during fiscal year 2025.

Does Fortress Biotech Inc buy back shares?

Yes, Fortress Biotech Inc (FBIO) spent $700K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Fortress Biotech Inc have outstanding?

Fortress Biotech Inc (FBIO) had 32M shares outstanding as of fiscal year 2025.

What is Fortress Biotech Inc's current ratio?

Fortress Biotech Inc (FBIO) had a current ratio of 2.49 as of fiscal year 2025, which is generally considered healthy.

What is Fortress Biotech Inc's debt-to-equity ratio?

Fortress Biotech Inc (FBIO) had a debt-to-equity ratio of 1.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fortress Biotech Inc's return on assets (ROA)?

Fortress Biotech Inc (FBIO) had a return on assets of 3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Fortress Biotech Inc's cash runway?

Based on fiscal year 2025 data, Fortress Biotech Inc (FBIO) had $79.4M in cash against an annual operating cash burn of $65.8M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Fortress Biotech Inc's Piotroski F-Score?

Fortress Biotech Inc (FBIO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fortress Biotech Inc's earnings high quality?

Fortress Biotech Inc (FBIO) has an earnings quality ratio of -9.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fortress Biotech Inc cover its interest payments?

Fortress Biotech Inc (FBIO) has an interest coverage ratio of -702.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Fortress Biotech Inc?

Fortress Biotech Inc (FBIO) scores 36 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.